Ernesto L Schiffrin
Ernesto L. Schiffrin, C.M., MD, PhD, FRSC, FRCPC, FACP, FAHA, is Distinguished James ºÚÁÏÍø±¬³Ô¹Ï Professor, Department of Medicine, ºÚÁÏÍø±¬³Ô¹Ï, Physician-in-Chief Emeritus, Jewish General Hospital, and Director of the Hypertension and Vascular Research Unit, Lady Davis Institute and the JGH Cardiovascular Prevention Centre. He was JGH Physician-in-Chief and ºÚÁÏÍø±¬³Ô¹Ï Department of Medicine Associate Chair from January 2006 to July 2023. He is a specialist in General Internal Medicine subspecializing in cardiovascular medicine and hypertension.
Dr. Schiffrin’s research addresses mechanisms and treatment of hypertension. He is author of 641 publications, many book chapters and editor of four books. His h-index is 137. He was President, Canadian Hypertension Society (1991–92); Chair, Council on Hypertension, American Heart Association (2002–04); President, International Society of Hypertension (2012–14); and President, Hypertension Canada (2013–16). He was Associate Editor of Hypertension, journal of the American Heart Association (06/2003–09/2015), and is Editor-in-Chief of the American Journal of Hypertension (01/2016–12/2025).
Dr. Schiffrin has received many awards, among others: Senior Investigator Award, Canadian Society of Internal Medicine (2003); Fellow, Royal Society of Canada (2006); Irvine Page–Alva Bradley Lifetime Achievement Award, Council on Hypertension, American Heart Association (2007); Bjorn Folkow Award, European Society of Hypertension (2010); Member of the Order of Canada (2010); Excellence Award in Hypertension Research, AHA (2011); Robert Tigerstedt Award, American Society of Hypertension (2013); Distinguished Scientist Award, Canadian Cardiovascular Society (2013); Margolese National Prize on Heart Disorders, UBC (2016); Prix Galien Recherche Award (2017); Distinguished Fellow of the International Society of Hypertension (2018); International Society of Hypertension Franz Volhard Award (2021); Distinguished Scientist of the American Heart Association (2021); and Lifetime Achievement Award, Hypertension Canada (2023).
These awards recognize Dr. Schiffrin’s pioneering translational work leading to the discovery of mechanisms involved in the remodeling of small resistance arteries in experimental and human hypertension. His groundbreaking research demonstrated that antihypertensive therapy electively causes regression of vascular remodeling in hypertensive patients. His seminal studies on angiotensin II, aldosterone and endothelin have elucidated the importance of these hormones in the vascular biology of hypertension. More recently, he was among the first to propose the inflammatory and immune theory of hypertension.